TY - JOUR T1 - Measuring patient experience of Cytosponge using the Newcastle ENDOPREM JF - Frontline Gastroenterology JO - Frontline Gastroenterol DO - 10.1136/flgastro-2022-102288 SP - flgastro-2022-102288 AU - Laura Jane Neilson AU - Rebecca C Fitzgerald AU - Jennifer Deane AU - Irene Debiram-Beecham AU - Linda Sharp AU - Colin J Rees Y1 - 2022/10/19 UR - http://fg.bmj.com/content/early/2022/10/19/flgastro-2022-102288.abstract N2 - Cytosponge is an exciting novel technology for oesophageal pathology diagnosis. Uses include screening for Barrett’s oesophagus, Barrett’s surveillance and triage of patients with chronic reflux symptoms. Cytosponge performs well in Barrett’s oesophagus diagnosis, with a specificity of >92% and sensitivity of 80% in intention-to-treat analyses in a case–control study.1 Furthermore, a cluster-randomised controlled trial demonstrated that offering Cytosponge to individuals with chronic reflux increased Barrett’s diagnoses by over 10 times compared with usual care.2The need to reduce the burden on endoscopy services (exacerbated by the COVID-19 pandemic) expedited the pilot implementation of Cytosponge into national care pathways. Cytosponge can prioritise upper gastrointestinal (GI) endoscopy with high sensitivity and specificity for high grade dysplasia and early cancer.3 UK policy-makers strongly support real-world implementation studies with independent evaluation.Patient experience is a crucial marker of quality of GI procedures and impacts patient attendance and reattendance. All patient-reported experience measures should be patient centred; derived from and completed by patients.4 Previous GI endoscopy patient experience … ER -